NGM Biopharmaceuticals (NGM) – Hot FDA News
-
NGM Biopharmaceuticals (NGM) CATALINA Phase 2 Trial of NGM621 Did Not Meet its Primary Endpoint
-
NGM Biopharmaceuticals (NGM) Phase 2b ALPINE 2/3 Study of Aldafermin in NASH Did Not Meet Primary Endpoint
-
Back to NGM Stock Lookup